Contributed by NAMPA / AFP.
Press Release from Business Wire : Biogen
ATTENTION - Usable ///
CAMBRIDGE, Feb 14, 2018 (BSW) - Biogen
(Nasdaq: BIIB) and Ionis
Pharmaceuticals, Inc. (Nasdaq: IONS) announced end of study results
from CHERISH, the Phase 3 study evaluating SPINRAZAź
(nusinersen) for the treatment of individuals with later-onset spinal
muscular atrophy (SMA), were published today in The New England Journal of Medicine. The full manuscript titled, "Nusinersen Versus
Sham Cont ...